Sight Sciences (NASDAQ:SGHT) Posts Quarterly Earnings Results, Meets Estimates

Sight Sciences (NASDAQ:SGHT) posted its quarterly earnings results on Wednesday. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12), FiscalAI reports. The business had revenue of $24.92 million for the quarter, compared to analysts’ expectations of $23.55 million. Sight Sciences had a negative return on equity of 43.39% and a negative net margin of 35.69%.

Here are the key takeaways from Sight Sciences’ conference call:

• Sight Sciences reported record third-quarter revenue of $24.9 million, up 25% year over year, and raised 2026 revenue guidance to $92 million–$93 million, implying about 20% growth. Adjusted operating expense guidance was maintained at $92 million–$94 million.
• IDE revenue reached a record $3.9 million, up 45% sequentially, prompting the company to raise its full-year IDE outlook to approximately $12 million. Ordering accounts and utilization both increased, though TearCare growth remains concentrated in a limited reimbursed footprint and broader payer access is not yet assured.
• IG revenue grew 7% to $21 million, with active accounts at a record high; full-year IG guidance was raised to $80 million–$81 million. The company launched its next-generation OMNI Ultra in the U.S. and said expanded Aetna coverage adds about 25 million covered lives.
• Cash used in the quarter fell to $2.4 million from $9.1 million a year earlier, while year-to-date cash use improved 48%; the company ended the quarter with $77.4 million in cash. Management said it remains focused on cash-flow breakeven and extended the debt interest-only period through August 2027.

Sight Sciences Trading Up 2.8%

NASDAQ SGHT traded up $0.26 on Wednesday, reaching $9.68. The company had a trading volume of 629,733 shares, compared to its average volume of 274,743. The stock’s 50 day moving average is $8.63 and its 200-day moving average is $6.03. The stock has a market cap of $533.27 million, a price-to-earnings ratio of -17.29 and a beta of 2.44. The company has a quick ratio of 4.67, a current ratio of 4.95 and a debt-to-equity ratio of 0.58. Sight Sciences has a 52 week low of $3.38 and a 52 week high of $10.06.

Analyst Ratings Changes

A number of research analysts have issued reports on SGHT shares. Weiss Ratings restated a “sell (e+)” rating on shares of Sight Sciences in a research report on Friday, August 7th. Citigroup raised their target price on shares of Sight Sciences from $8.00 to $10.00 and gave the company a “neutral” rating in a research note on Monday, October 5th. Wall Street Zen upgraded shares of Sight Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. HC Wainwright assumed coverage on shares of Sight Sciences in a research note on Thursday, October 15th. They set a “buy” rating and a $14.00 price target for the company. Finally, UBS Group increased their price objective on shares of Sight Sciences from $7.00 to $8.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.25.

Insider Buying and Selling

In other news, CEO Paul Badawi sold 29,653 shares of the company’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $9.05, for a total value of $268,359.65. Following the completion of the sale, the chief executive officer directly owned 6,092,819 shares of the company’s stock, valued at $55,140,011.95. This represents a 0.48% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CTO David Badawi sold 7,797 shares of the stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $9.05, for a total transaction of $70,562.85. Following the completion of the sale, the chief technology officer owned 1,975,075 shares in the company, valued at $17,874,428.75. This represents a 0.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 47,646 shares of company stock worth $429,157 in the last ninety days. 30.40% of the stock is currently owned by corporate insiders.

Sight Sciences Company Profile

Sight Sciences, Inc is an ophthalmic medical technology company focused on developing and commercializing products designed to address the underlying causes of certain eye diseases. The company’s portfolio is centered on minimally invasive and non-invasive procedures intended to improve patient outcomes while supporting physicians in the treatment of glaucoma and ocular surface disease.

Its primary products include the OMNI Surgical System, a minimally invasive glaucoma surgery device used to reduce intraocular pressure by improving the eye’s natural fluid outflow pathways, and the TearCare System, a thermal pulsation technology designed to treat meibomian gland dysfunction, a common cause of evaporative dry eye disease.